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Summary

This survey examines the extent to which live chimpanzees have been used in monoclonal antibody (mAb)
research and the drug approval process. The survey covers 193 scientific articles published during
the years 1981-2010, as well as preclinical studies leading to the approval of mAb drugs by the Food and
Drug Administration of the United States. The frequency of the articles has decreased by more than twothirds from their highs in the late 1980’s, and the aggregate number of chimpanzees used in these studies
has decreased by more than 90%.
The experimental protocols ranged from single or multiple blood draws to extraction of body fluids and
tissue samples, and to multiple, repeated organ biopsies. Many studies involved infecting the chimpanzee(s)
with pathogenic organisms and immunization and infusion protocols. Addressing the health history
and status of the chimpanzees was an exception rather than the rule, and anesthesia and analgesia were
mentioned only in a small minority of the surveyed articles.
In the past two decades, the FDA has approved 32 mAb drugs, but only three of those drugs could
be determined to involve the chimpanzee in the preclinical stage. Two of those three drugs have been
withdrawn from the market due to their severe adverse effects in human patients. Available alternatives,
together with ethical and economic reasons, suggest that the use of the chimpanzee in this manner
may not be necessary or appropriate.
Keywords: Chimpanzee, monoclonal antibodies, preclinical studies, animal model

1 Introduction

Since their discovery in the 1970’s, monoclonal antibodies
(mAbs) have rapidly become an important tool in life sciences research and one of the most fast-growing products of the
pharmaceutical industry. More than 30 mAb drugs have been
approved to date by the U.S. Food and Drug Administration
(FDA), and hundreds of mAbs have been tested in clinical trials, particularly in the fields of immunotherapy and oncology
(Strohl, 2009).
The key characteristic of a mAb is its ability to bind to a specific molecular target, based on the chemical and conformational
complementarity of the mAb and the target (Brekke and Sandlie,
2003). Although mAbs initially might have been thought of as
a high-technology version of natural antibodies (Ig), to be used
in therapy like serum and polyclonal antibodies, their special
properties soon gave rise to new applications. The therapeutic
targets of mAbs now consist largely of receptors and soluble
ligands, and a mAb can be used as an “address label” to deliver
a toxin or another drug to the appropriate molecule (Alley et al.,

2009). In cancer therapy, for example, mAbs can be conjugated
with toxins or radionuclides to treat or image tumor cells.
The unique characteristics of mAbs influence preclinical studies of mAb drugs, including the selection of an animal model.
As with other drugs, pharmacokinetics and -dynamics (PK &
PD) studies are a critical part of preclinical studies. With mAbs,
however, PK & PD studies typically are more complex than
those for small-molecule drugs. For example, because of their
large molecular size, mAbs are not eliminated renally for the
most part but, rather, through secretion or catabolism, depending on the type of mAb (Wang et al., 2008). Species-specific
affinity of a mAb for relevant epitopes, in turn, may extensively
affect its elimination rate (Loisel et al., 2007). Immunogenicity
also has received attention, as increasingly humanized mAbs
may prove immunogenic in animals used in preclinical studies
(Wang et al., 2008).
Some primate researchers assert the importance of the chimpanzee model in the development of mAb drugs. While detailed scientific justifications of that argument have not been
set forth, the main gist of the argument appears to be the chim-
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panzee’s phylogenetic proximity to humans and the human immune system (VandeBerg et al., 2006). Moreover, the argument
notes that many pharmacological mAb studies already use the
chimpanzee. Are chimpanzees, then, truly the animal model of
choice in current pharmacological mAb studies – and for future
studies as well?
This article sets forth, first, a comprehensive and systematic
review of three decades of published peer-reviewed scientific
literature that deals with the use of the chimpanzee in mAb research. The analysis of these scientific studies includes, in addition to their frequency, types of research involved, numbers
of chimpanzees used, both in the aggregate and in individual
studies, and procedures used on chimpanzees.
Second, this article goes on to review the approval of mAb
drugs by the FDA to ascertain to what extent the chimpanzee
has been used as a preclinical animal model in this context. Finally, the discussion section addresses prospective uses of the
chimpanzee in mAb research, including whether such use is
necessary or appropriate.
2 Methods
2.1 Survey of scientific articles

Scope
PubMed is a comprehensive search and retrieval engine of scientific literature maintained by the U.S. National Library of
Medicine (The National Institutes of Health, PubMed, http://
www.ncbi.nlm.nih.gov/sites/entrez). To identify articles that
deal with the use of the chimpanzee in mAb research, PubMed
was searched with “chimpanzee AND monoclonal AND antibody,” limiting the search to articles in the English, German,
and French languages. This left out three articles in the Japanese
language and one in Russian. The first entry in the results dated
from December 1981. Consequently, the date range for the survey was defined as the period of Jan.1, 1981 through Dec. 31,
2010. This search produced 274 results.
Next, it was necessary to identify, among the 274 articles,
those that did not deal with original research or that did not actually use live chimpanzee(s). As a result of this initial review,
20 articles were found to consist of reviews, opinion pieces, or
commentaries. Another 26 articles, while dealing with original research, did not actually use the chimpanzee; they merely
mentioned it, usually by reference to another research project.
Yet another 18 articles involved an analysis of biological or
genetic properties of the chimpanzee, but the sample(s) in
question had been retrieved from a genetic data bank, such as
GenBank, or the study used a cell line provided by another laboratory. Four articles dealt with research performed on tissues
or organs removed from necropsied chimpanzees, and since
these articles did not involve live chimpanzees, they were
omitted from subsequent, more detailed analyses. Finally, 13
articles – all dating from before 1990 – could not be located
for further analysis.
The elimination of the above sub-categories of articles left
193 articles that involved both mAb research and the use of the
live chimpanzee. These 193 articles form the base for this sur104
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vey. It should be pointed out, however, that this article base is
likely to underestimate the extent of the use of the chimpanzee in this segment of scientific research. For example, private
companies and laboratories do not publish most of the results
of their research for proprietary reasons; governmental research
may be kept confidential for various reasons; and many other
projects are not written up for publication because the project
or the results or logistical problems may make it undesirable or
unfeasible. Nevertheless, it appears likely that this survey, even
if not all-inclusive, is representative of the practices and trends
in this area and, as such, provides useful information.
Trends
Overall trends regarding the use of the chimpanzee in mAb research may be of broader interest for a number of reasons, such
as determining possible shifts in the animal models used by
the research community. This survey period consisted of three
decades, which suggested interrogating relevant trends either
by each of the three decades or by 5-year periods. In the end,
the 5-year periods were selected, because this would yield more
data points and, therefore, more detail.
Ambiguities
As discussed in more detail later, there were frequent and substantial gaps in the data in the articles. Ambiguities were particularly frequent in ascertaining the numbers of chimpanzees.
Many articles did not state the number of chimpanzees at all.
Some others used the singular in describing the chimpanzee
use, but this might mean that only one chimpanzee was used
or it might signal the species in general. The plural form of the
chimpanzee might mean two or any higher number. Therefore,
it seemed best simply to base the chimpanzee count on articles
where a specific number could be discerned. In this respect, if
the data tables or figures indicated a certain number, that number
would be used, even if the article text did not state how many
chimpanzees had been used.
Citations to examples
Citations to relevant articles are provided where the results and
conclusions from the survey are discussed. Because of the large
survey base, however, it was impractical to cite all the relevant
articles for each given statement. Therefore, where multiple articles from the survey could be cited as examples, this article
provides, by way of examples, citations to two articles, in order
to constrain the page and citation numbers of this survey. More
than two examples may be given, if the examples provide a representative range of studies.
2.2 Review of approved mAb drugs

The review of the regulatory approvals of mAb drugs in the
United States was based on documents made available on the
FDA web site. The web site provides, however, only selected
parts of the agency record, as opposed to the entire record, and
even the available documents have redactions made pursuant to
the exemptions in the Freedom of Information Act. A number
of Freedom of Information Act requests have been made to the
FDA for additional information regarding a number of these
Altex 28, 2/11
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drug approvals, but by press time no answer had yet been received from the agency. Therefore, this analysis is by necessity
restricted to the information currently available on the FDA web
site. One might presume, however, that the selected records the
FDA makes available are those that it considers to contain the
most relevant information regarding the approval.
Both in the United States and internationally, the accepted
nomenclature classification for nonproprietary drugs designates
the suffix “-mab” for monoclonal antibody drugs (World Health
Organization, 2009). Therefore, our review and analysis of
FDA approvals was restricted to drugs specifically identified as
mAbs through that suffix. Other drugs also have been approved
that have many functional similarities with mAbs. These drugs
combine the target-specificity of a mAb as a drug-delivery vehicle, with a small molecule or a fusion protein to target another
molecule, such as a cytokine. Such other classes of drugs fall
outside this review.
3 Results
3.1 Survey of scientific articles
3.1.1 Frequency of articles

The 193-article base was first sorted by publication year, and
the articles then were grouped by 5-year periods into six groups
to show what trends, if any, could be observed in this regard.
Figure 1 shows as the first data series the number of all articles
in a given group. As the second data series, Figure 1 shows the
numbers of articles that provided specific information regarding
the number of chimpanzees used in the research in question.
This issue will be relevant, as we will discuss later the numbers
of chimpanzees used in mAb research.
In the first half of the 1980’s, the number of published articles
was only 19, as mAb technology was still new and not within

the reach of all researchers. The number grew rapidly to 58 in
the latter part of that decade, but then started a decline. In the
latter part of the 1990’s, that decline was nearly 50% of the early
1990’s (28 v. 52), and reached even lower values, 19 and 21, for
the most recent decade.
The proportion of peer-reviewed “chimpanzee mAb” articles
of all peer-reviewed mAb articles also continues to decrease.
The percentage of chimpanzee mAb articles of a PubMed
search for “monoclonal AND antibody” (accessed 01/31/11 and
excluding reviews) for the period of 1981-1990 is 0.14%, and
for the period of 1991-2000, 0.1%. For 2001-2010, that percentage is less than 0.07%.
3.1.2 Number of chimpanzees involved
in the studies

Aggregate numbers
To arrive at aggregate numbers, only those articles where a specific number was given for the chimpanzee(s) were included in
the following analysis. Figure 2 shows two data series in this
respect. The first gives the aggregate number of chimpanzees
in a given period, based on a straightforward summing up of
the relevant numbers. During 1986-1995, however, there were
five articles that each discussed studies where blood samples
were obtained from a very large number of chimpanzees, and it
seemed possible that these five articles might skew the figure.
Therefore, the second data series presents the aggregate chimpanzee numbers without these extreme cases.
For the first, unadjusted data series Figure 2 shows a rapid
climb from the early 1980’s over the next decade to reach the
peak of 1,213 chimpanzees in the period of 1991-1995. The next
5-year period saw a sharp drop to 91 chimpanzees, and the most
recent decade shows that 28 and 33 chimpanzees, respectively,
were used in the studies published in its 5-year periods.
On the other hand, if we were to look for the number of individual chimpanzees used in these studies, it is likely that some

Fig. 1: Frequency of articles dealing with live chimpanzees in mAb research
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Fig. 2: Number of chimpanzees in mAb studies

chimpanzees had been used in multiple studies. From that perspective, the total aggregate number may be an over-count of
the individuals. Unfortunately, the often sketchy information
provided in the surveyed articles does not permit a reliable estimate of the individual chimpanzee number based on all of the
published studies.

ous decades. Also, in the last decade, no studies used more than
10 chimpanzees. The most common number across the three
decades (in 42% of the articles) is one or two chimpanzees per
study. The peak numbers of chimpanzees used per study occurred in 1991-95.

Number of chimpanzees in a given experiment
The lack of specific information regarding the chimpanzees
used in the studies makes it impractical to attempt an acrossthe-board estimate of the numbers of chimpanzees in individual
studies. Based on those articles that gave a specific number,
however, the following counts could be made (Tab. 1).
The numbers in the table suggest several observations: For
example, experiments in the most recent decade (2001-10) generally used smaller numbers of chimpanzees than in the previ-

The 1980’s witnessed the application of the new mAb technology to biomedical sciences. This was reflected in survey
articles, in that many of the reviewed mAb articles dealt with
basic-type mAb science, such as comparing antigenic properties of red and white blood cells (Neubauer et al., 1981; Socha
and Ruffie, 1990). While many studies found cross-reactivity
with human and chimpanzee epitopes, such findings were by no
means uniform, and a number of studies confirmed differences
between humans and chimpanzees (Hammond and Robinson,
1984; Palmer et al., 1987; Lu et al., 1987). In some cases, a mAb
would not bind to chimpanzee antigens, although it did so with
human and other non-human primate antigens (Dowell et al.,
1984; Shaw, 1986).
In the latter part of the 1980’s, the mAb technology was being applied to increasingly diverse components of the immune
system and to infectious disease investigations, such as AIDS,
hepatitis, and leukemia (Iwarson et al., 1985; Winton et al.,
1985; Goudsmit et al., 1987). It was thought that if conventional vaccines could successfully prevent disease by building
humoral immune memory, mAbs could be used in a similar
manner to prevent newly-identified viral diseases. The chimpanzee was believed to be a useful animal model to researchers because many mAbs would bind both to human and chimpanzee antigens, and laboratory reagents developed for human
use thus could be used in chimpanzee studies (Ehrlich et al.,
1988; Moller et al., 1990). For example, the chimpanzee was
used extensively to search for immunomodulatory mAbs and to

Tab. 1: Number of chimpanzees used in an individual study*
*Where the article describing the study gives a specific number.

1-2

3-5

6-10

11-20

21-99

>100

1981-1985

4

4

3

1

1

0

1986-1990

19

12

5

3

3

1

1991-1995

16

7

7

4

2

4

1996-2000

6

6

2

3

0

0

2001-2005

4

3

3

0

0

0

2006-2010

8

3

1

0

0

0

Period

##
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observe infusion reactions following their administration (Van
Meurs and Jonker, 1986; Jonker et al., 1988).
In the 1990’s, many published articles on mAb studies with
chimpanzees continued to focus on properties of the serum and
the immune response. Again, while similarities were found between the human and the chimpanzee in these respects, many
articles also noted differences (Blancher and Socha, 1991; Socha and Moor-Jankowski, 1993). Some researchers specifically
focused on erythrocytes and related molecules, and their studies typically compared characteristics of samples from humans,
great apes (hominoids), and other non-human primates (Blancher et al., 1992; Socha et al., 1993). Nine articles described the
use of chimpanzees in endotoxemia experiments, attempting to
explain molecular causes of sepsis (Levi et al., 1994, 1998). A
number of articles investigated immunomodulatory properties of
lymphocytes and cytokines, including reactions that frequently
result from the infusion of therapeutic mAbs (Rao et al., 1991;
Logdberg et al., 1994). Articles from this decade also frequently
deal with research on HIV- and hepatitis-related mAbs (Emini
et al., 1992; Sawada et al., 1995; Zhou et al., 1999).
In the 2001-2010 decade, perhaps partly due to the smaller
number of articles, the distribution of study topics was more
heterogeneous. While the procedural features of the studies
varied, the majority of articles could be broadly categorized as
dealing with infectious disease studies (Esumi et al., 2002; Men
et al., 2004; Hatziioannou et al., 2009). A few articles discuss
the effectiveness or properties of immunomodulatory mAbs
(Newman et al., 2001; Boon et al., 2002).
3.1.4 Experimental procedures

Chimpanzee experience in general
Typically, the information in the articles regarding the treatment
of chimpanzees was minimal or non-existent. The majority did
not describe the type or manner of procedures applied to the
chimpanzees, their health status before, during, or after the experiment, or conditions in which they were housed and cared for.
Usually, the information only dealt with the type of biological
sample(s) obtained from the chimpanzee. Only a small minority
of the articles provided information regarding the administration, type and length of anesthesia, measurements of clinical
data, and apparent health and well-being of the chimpanzees
before, during, and immediately after the experiment.
Blood samples
All of the experiments appeared to involve blood draws either
before, during, and/or after the experiment, even if this was
not explicitly stated in the article. These were required either
for the analysis of the mAbs and their effects, or for observing the infection stage of the chimpanzees, and in general to
determine the health status of the chimpanzees. Even if a blood
draw was explicitly mentioned, in most cases it was a short
statement without further elaboration, such as: “Serum samples from two chimpanzees … were tested ….” (Maillard et
al., 2001), or “[a] blood sample was collected weekly from
each animal …” (Men et al., 2004).
Sometimes, a blood sample appeared to be the only invasive
procedure, such as in many studies in the 1980’s where the
Altex 28, 2/11
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analysis of the components of serum or plasma was the main
objective of the studies. In many cases, however, the study required a series of blood draws, either within a relatively short
time period (such as 2-12 weeks) but also for extended periods,
as in many hepatitis experiments. In those studies, weekly or
biweekly draws would be done for over a year or several years
(Zhang et al., 2006; Ogata et al., 1993).
Tissue samples and biopsies
In addition to blood draws, many studies also required more
invasive procedures, such as one or more bone marrow aspirations, or biopsies of lymph nodes and/or liver, and/or other
tissue samples (such as kidney, spleen, or lung), and catheterization for urine samples (Kim et al., 2008; Geijtenbeek et al.,
2001; Borke et al., 1987; Thirkell et al., 1990). The type of biopsy (such as needle, laparoscopic, or surgical biopsy) was usually
not specified. In the case of long-running studies (Goncalvez et
al., 2008), a chimpanzee might be subjected to dozens of liver
biopsies or other tissue biopsies (Bukh et al., 2008).
Some more recent studies involved bone marrow sampling
(single or repeated), by bone marrow aspiration or biopsy
(Schofield et al., 2000; Men et al., 2004; Goncalvez et al.,
2008). Bone marrow is the source of blood cells (hematopoiesis) and, due to advances in biochemical techniques, may provide ever-increasing amounts of information about the physical
and chemical characteristics of blood cells and related molecules. While a less frequent occurrence, researchers in a 2002
reproductive study obtained samples of the chimpanzee spleen,
external and internal reproductive tract, and sperm from a contractor housing primates (McCauley et al., 2002). In a 1982
study, spleens were removed entirely from 19 chimpanzees
before they were infected with malaria in order to observe the
immune response in the absence of this important lymphoid
organ (Nardin et al., 1982).
Infectious agents
A large portion of the studies involved infecting chimpanzees
with a bacterial or viral pathogen that would cause an infectious
disease, or injecting them with a toxic compound that would
cause typical symptoms of the disease in question. HIV and
hepatitis were by far the most frequent pathogens used in this
manner (Wang et al., 1999; Bukh et al., 2008). Others included
smallpox, Dengue fever, anthrax, human T-cell lymphoma virus
(HTLV), herpes, respiratory syncytial virus, tuberculosis, encephalitis, and malaria (Chen et al., 2006a,b; Men et al., 2004;
Arp et al., 1996; Blewett et al., 1999; Crowe et al., 1994; Franzoso et al., 1993; Goncalvez et al., 2008; Klotz et al., 1996).
In a series of experiments, E. coli was used in amounts sufficient to trigger symptoms of endotoxemia that would mimic
early phases of sepsis (Levi et al., 1998; Jansen et al., 1995). In
other experiments chimpanzees would be induced to develop
plaques in brain tissue, asserted to be similar to those found in
Creutzfeld-Jacob disease (Toh et al., 1985).
Generally, amounts of infectious agents used in the studies
were significantly larger than what had previously been found
to be sufficient to cause infection in chimpanzees. (The infectivity is measured in CID – a chimpanzee infectious dose suf107
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ficient to infect at least 50% of the chimpanzees that the doses
had been tested on.) For example, one recent study infected the
chimpanzees with 1000 CID-50 of hepatitis B virus (HBV), and
55 weeks later, one chimpanzee was challenged again with the
same dose of HBV (1000 CID-50) (Zhang et al., 2006). The
studies do not discuss reasons for a particular dose.
The methods used to introduce the infectious micro-organism
into chimpanzees varied. Frequently, chimpanzees were injected intravenously or intramuscularly with the virus or bacteria,
but some studies described the method of infection as “intrahepatic” or “intratracheal” (Emini et al., 1992; Franzoso et al.,
1993; Forns et al., 2000; Meunier et al., 2008).
In several studies, chimpanzees were infected with multiple
types of a disease, so-called “superinfection.” For example, in
some experiments involving hepatitis or Dengue fever vaccines, the chimpanzees were infected with all known genotypes
of the virus in order to induce the chimpanzees to produce a
wider repertoire of virus-specific antibodies (Men et al., 2004;
Schofield et al., 2002).
Vaccines and mAb infusions
Passive immunization confers protection from pathogens or
toxins through antibodies that neutralize those pathogens.
Many chimpanzee experiments, therefore, investigated the use
of mAbs as a vaccine or as a means to neutralize infectious
or toxic agents. This requires that large amounts of mAbs be
introduced into a chimpanzee, which would typically be accomplished by infusion (Ogata et al., 1993; Wang et al., 1999).
Similarly, large amounts of mAbs are needed to block molecular receptors sufficiently, as in the case of mAbs that were
developed to repress immune function for therapeutic reasons
(such as in leukemia or autoimmune diseases) (Fishwild et al.,
1999; Rao et al., 1991).
It was recognized that mAb and infusion procedures could
cause unpleasant side effects, and sometimes even life-threatening complications. Typically, during an infusion a drug or another chemical compound is administered intravenously through
a needle or a catheter while the animal is under some type of anesthesia, such as ketamine and/or gaseous anesthesia (N2O, O2,
halothane mixture) (Jonker et al., 1993). In the 1990’s, a number
of chimpanzee studies investigated different mAb variants and
different doses that might minimize or eliminate such undesirable effects. In these studies, some chimpanzees demonstrated
severe adverse effects, such as in a study where a chimpanzee
developed a fever of 40°C (104°F), requiring treatment with ice
packs (Rao et al., 1991). Some mAbs brought on other severe
symptoms, such as shock-like symptoms, respiratory difficulties, irregular heartbeat, cyanosis, jerking, and/or vomiting (Parleviet et al., 1990; Jonker et al., 1993; Harpprecht et al., 1990).
If, on the other hand, side effects were deemed minimal or transitory, the article would merely note that fact without further
elaboration. One endotoxemia study noted that while there were
changes in some cell populations obtained from the chimpanzees, these changes were consistent with a “stress response to
the infusion procedure” (Fishwild et al., 1999).
Experiments to develop vaccines for active immunity would
typically require multiple injections, such as an initial immuniza108

altex_2011_2_103_116_Bettauer.indd 108

tion and subsequent booster(s) (Chen et al., 2006b). In a hepatitis
C study, a chimpanzee was vaccinated 13 different times with
epitope(s) and adjuvants over a 34-week period, and was challenged twice with HCV (Esumi et al., 2002). In some cases, such
as those involving DNA vaccines, a series of immunizations
would be performed on each chimpanzee (Forns et al., 2000).
3.1.5 Chimpanzee health and welfare

Pre-study health status
The reviewed articles typically contained little or no information
pertaining to the chimpanzees’ past or overall health and welfare
that might have influenced the mAb study results. Only a few
articles gave information on age, sex, weight, and possible prior
exposure to infectious disease(s) (Crowe et al., 1994; ten Cate et
al., 1993). Since the early 1990’s, many articles – approximately
25% – contained a statement that the procedures observed in
the study complied with the applicable institutional animal care
guidelines (Chen et al., 2006a; McCauley et al., 2002).
Anesthesia and analgesia
As a rule, there was no mention of any anesthesia in the context of bleeds. In some instances where the procedure appeared
to be more complex, such as a lengthy process that combined
bleeds, infusions and/or biopsies, ketamine chloride or nitrous
oxide and halothane were reported as having been administered
(Geijtenbeek et al., 2001; van der Poll et al., 1996; Levi et al.,
1998). It is possible, of course, that anesthesia and analgesia
were provided in other studies, but the description of the procedure lacked such information.
Control animals
The experience of chimpanzees used as control animals in infectious disease studies also merits consideration. Like experimental chimpanzees, they were subject to frequent blood draws,
biopsies and other experimental procedures. However, while
chimpanzees in experimental groups frequently suffered from
side effects of pathogenic infection or toxemia, in some cases
mAb therapy might at least temporarily ameliorate the symptoms of the disease. Control chimpanzees did not have this benefit (Forns et al., 2000; Sawada et al., 1995).
Origin of chimpanzees
The majority of chimpanzees currently in U.S. laboratories were
captured from the wild or are descendants of wild-caught chimpanzees. Some chimpanzees are former pets or were used in the
entertainment industry prior to being given up to research. Importation of wild-caught chimpanzees into the US has been prohibited since 1977. While most U.S. and European researchers do
not use chimpanzees in situ in Africa for their mAb studies, our
review indicated that some studies describe such research. For example, one study obtained blood samples from Central and West
African chimpanzees in order to compare hepatitis B virus strains,
and after identifying an unusual strain, the researchers concluded
that more testing in central Africa needed to be done to confirm
the results of this study (Takahashi et al., 2001). Other studies
used chimpanzees and other hominoids housed at an institute in
Franceville, Gabon (Apoil et al., 1997; Tournamille et al., 2004).
Altex 28, 2/11
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3.2 Approval of mAb drugs
3.2.1 Requirements for non-clinical
animal studies

The International Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals for Human
Use (ICH), to which the United States is a party, has issued guidance regarding the preclinical (non-clinical) safety evaluation of
biotechnology-derived drugs (biologics) (ICH, 1997). Section
3.3. of this guidance (S6) states specifically that the relevant
animal species for testing of monoclonal antibodies should express the desired epitope and demonstrate a similar tissue crossreactivity profile as for human tissues. Such testing is intended
to optimize the ability to evaluate toxicity arising from the binding to the epitope and any unintentional tissue cross-reactivity.
The ICH guidance recognizes, however, that in the absence of a
relevant animal model, relevant transgenic animals that express
the human receptor or the use of homologous proteins should be
considered (ICH, 1997).
Consistent with its statute and the ICH guidance, the FDA
has not set forth any hard-and-fast requirements regarding the
animal species to be used in preclinical testing. Specifically,
there is no FDA requirement that would obligate pharmaceutical companies to use the chimpanzee. A flexible regulatory approach is necessary because each mAb product is unique, and
therefore the most appropriate scientific means for testing safety
and toxicity must be arrived at through individual analysis in
each case (Bhogal et al., 2008).

3.2.2 mAb drug approvals

The documents publicly available on the FDA web site show
that the agency approved for distribution the first mAb drug,
muromonab OKT3, in 1992 (FDA, 2010a)1. By 12/31/10, the
FDA had approved 32 mAb drugs, of which 28 currently remain on the market (FDA, 2010b).
Of the 32 approvals, the FDA web site has information about
preclinical animal studies for 28 drugs. No information on animal studies could be found for muromonab-OKT3, fanolesomab (discontinued in 2008), nofetumomab, and trastuzumab.
Table 2 lists these 28 drugs chronologically based on the approval date. The table also indicates which species, according
to the available information, were used in preclinical studies.
The information made available by the FDA indicates that
the preclinical information for only three of the approved
drugs involved chimpanzees. Of those three drugs, only in the
case of infliximab was a more detailed description available of
the type of studies the chimpanzee was used for – and the drug
still remains on the market. For the majority of mAbs on the
market, cynomolgus macaques, in addition to mice, have been
used as the preferred species to test toxicology.
The FDA data indicate that of the 28 drugs, only three have
been withdrawn from the market, and for one of these, daclizumab, the withdrawal was due to business reasons rather than
serious adverse safety issues. The only two withdrawals that
involved significant safety issues for human patients involved
the drugs efalizumab and gemtuzumab, each of which had used
the chimpanzee in its preclinical studies.

1 Other available information indicates that the very first FDA approval for this drug dates from 1986, but it is not clear whether
this statement refers to the approval for investigation (IND) or distribution (Strohl, 2009).

Tab. 2: Therapeutic mAb drugs approved by the FDA with preclinical animal test information available
Drug / Trade name

Year approved / discontinued

Biological target

Species used in preclinical studies

Abciximab / ReoPro

1994

Platelet glycoprotein

Mouse, rat, dog, monkey, baboon

Capromab / ProstaCint
1996
		
		

A glycoprotein expressed
by the prostate specific
membrane antigen

Mouse, cynomolgus monkey,
rat, rabbit

Imciromab / Myoscint

1996

Myosin bound to DTPA

Rat, dog, non-human primate

Daclizumab / Zenapax

1997 / 2009 (not a safety issue)

IL-2R or CD25

Cynomolgus monkey

Rituximab / Rituxan

1997

CD20

Rat, cynomolgus monkey

Basiliximab / Simulect

1998

IL-2R (CD25)

Rhesus, cynomolgus monkey

Infliximab / Remicade
1998
TNF
			

Mouse, rat, beagle dog, chimpanzee,
cynomolgus monkey

Palivizumab / Synagis
1998
RSV (F protein, site A)
			

Cotton rat, cynomolgus monkey,
rabbit

Gemtuzumab / Mylotarg
2000 / 2010
CD33
			

Mouse, rat, cynomolgus monkey,
chimpanzee, beagle dog

Alemtuzumab / Campath

Mouse, cynomolgus monkey
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Drug / Trade name

Year approved / discontinued

Biological target

Species used in preclinical studies

Adalimumab / Humira
2002
TNF
			

Mouse, rat, guinea pig, rabbit, dog,
cynomolgus monkey

Ibritumomab tiuxetan /
Zevalin

2002

CD20

Mouse, rat, cynomolgus monkey

Efalizumab / Raptiva

2003 / 2009

CD11a

Mouse, chimpanzee

Omalizumab / Xolair

2003

IgE

Cynomolgus monkey

Tositumomab / Bexxar

2003

CD20

Cynomolgus monkey

Bevacizumab / Avastin
2004
VEGF
			

Mouse, rat, rabbit,
cynomolgus monkey

Cetuximab / Erbitux
2004
EGFR
			

Mouse, rat, rabbit,
cynomolgus monkey

Natalizumab / Tysabri
2004
α4β1 and α4β7 integrins
			

Mouse, guinea pig,
cynomolgus monkey, rhesus

Panitumumab / Vectibix
2006
EGFR
			

Mouse, rat, rabbit,
cynomolgus monkey

Ranibizumab / Lucentis
2006
VEGF
			

Rabbit, cynomolgus monkey,
guinea pig

Eculizumab / Soliris

CD52

Mouse

Certolizumab pegol / Cimzia 2008

TNF

Mouse, rat, cynomolgus monkey

Canakinumab / Ilaris

2009

IL-1β

Mouse, marmoset

Golimumab / Simponi

2009

TNF

Mouse, cynomolgus monkey, rhesus

Ofatumubab / Arzerra

2009

CD20

Mouse, cynomolgus monkey

Ustekinumab / Stelara

2009

IL-12, IL-23

Mouse, cynomolgus monkey

Tocilizumab / Actemra

2010

IL-6R

Mouse, cynomolgus monkey

Denosumab / Prolia

2010

RANKL

Mouse, rat, cynomolgus monkey

3.2.3 Infliximab

2007

Infliximab (trade name: Remicade™) is a chimeric mouse/human hybrid mAb. It was initially approved in 1998 to control
Crohn’s disease, a chronic inflammatory bowel disease, and in
2004, it was additionally approved to treat rheumatoid arthritis. In both diseases, infliximab reduces chronic inflammatory
symptoms by preventing the binding of tumor necrosis factor
alpha (TNFα) to its receptor and thus inhibits the activity of
TNFα (FDA, 1998).
Preclinical studies were conducted on mice, chimpanzees, cynomolgus monkeys, rats, rabbits, and beagle dogs. In addition,
cross-reactivity studies included the baboon, macaque, tamarin,
and pig. The chimpanzee TNFα was the only one, besides human, that bound infliximab, and therefore, in addition to the
pharmacokinetic studies, the chimpanzee was used in limited
safety studies. These involved 3-5 consecutive doses, each series
with a different dosing strength. The FDA review notes that the
chimpanzee safety studies conducted in 1993 showed no signs
110

altex_2011_2_103_116_Bettauer.indd 110

of toxicity. The documents also state, however, that because the
applicable restrictions prohibit necropsies on chimpanzees, the
studies could not provide histopathological data and were limited to clinical chemistry, hematology assessments, and clinical
observations (FDA, 1998).
Transgenic mice and surrogate antibodies were the main
means of providing preclinical safety and efficacy data. The
immunogenicity testing for infliximab was performed using the
cynomolgus monkey and the mouse. Efficacy was not tested
in the chimpanzee, although some immune response in them
was noted.
In contrast to preclinical studies, the clinical trials disclosed
a number of severe and less severe adverse effects in patients
that were not observed in the chimpanzee model. General side
effects included infusion reactions and immunogenicity, and
hypersensitivity reactions that bring on headache, nausea, and
arthralgia (FDA, 1999). Other adverse effects included immunosuppression (possibly predisposing to tuberculosis), reduced
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blood cell and platelet counts, malignancies, and elevated liver
enzymes. In August 2009, the FDA issued a safety alert to include leukemia and psoriasis among possible risks associated
with the use of a number of TNF blockers, including infliximab
(FDA, 2009b).
3.2.4 Efalizumab

Efalizumab (trade name: Raptiva™) is an immunosuppressant
that the FDA approved in 2003 for treating psoriasis. Although
the FDA approval letter mentions that the preclinical studies
included chimpanzees, the available documents provide only
fragmentary additional information regarding these studies.
The chimpanzee apparently was used in cross-reactivity
studies, since the documents state that efalizumab binds only
the human and chimpanzee immune molecule (LFA-1) that is
the target (Genentech, 2003; Bauer et al., 1999). The chimpanzee also was used in some pharmacokinetics and toxicology studies. The FDA documents note that chimpanzees were
exposed to a 6-month study involving up to a 339-fold dose
of the mAb, compared to the projected human dose, to evaluate its toxicology (Genentech, 2003). They also note that the
immune response of chimpanzees treated with this mAb was
reduced after injection of tetanus toxin (FDA, 2003). Due to
the lack of direct cross-reactivity of efalizumab in mice, a surrogate murine equivalent was developed to test its efficacy
(Genentech, 2003).
When efalizumab was approved, the FDA required Genentech to conduct seven additional clinical studies. However, reports of serious side effects caused Genentech, following urging by the FDA, to withdraw the drug from the market in 2009
before all of these trials had been completed and fully analyzed.
A similar measure took place in the European Union. The FDA
notice regarding the withdrawal mentions specifically three
incidents of progressive multifocal leukoencephalopathy, that
is, inflammation of brain matter due to viral infection and/or
immune deficiency (FDA, 2009c). Other adverse effects noted
in clinical trials and post-marketing practice included anemia
and thrombocytopenia (deficiency of blood platelets, resulting
in bleeding); inflammatory immune-mediated events; serious
infections; and worsening of psoriasis (FDA, 2003).
3.2.5 Gemtuzumab ozogamicin

Gemtuzumab ozogamicin (trade name: Mylotarg™) is a chemotherapeutic drug for treating a form of bone marrow cancer
(acute myeloid leukemia, or AML). It consists of two parts, a
monoclonal antibody and a cytotoxin. The monoclonal antibody is specific for the CD33 molecule that is expressed on the
surface of early myeloid leukemia cells and leukemic cells of
a majority of AML patients. The antibody is combined with a
cytotoxic antibiotic, calicheamicin, which the antibody delivers
to the cancer cells in order to destroy them.
The preclinical toxicity review involved mice, rats, and monkeys whose liver toxicity levels appeared to be concordant with
humans (FDA, 2000). The FDA documents indicate, however,
that early toxicity studies also involved chimpanzees and dogs.
The sole chimpanzee study involved a 2-hour infusion of the
drug into two chimpanzees who then were monitored for two
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weeks. Although some abnormalities were noted, it was assumed these may have been associated with the ketamine anesthesia (FDA, 1996).
The FDA granted gemtuzumab accelerated approval in May
2000, but the sponsoring company was required to conduct additional clinical trials after the approval to confirm the drug’s
benefit. One of these post-approval clinical trials raised new
concerns about the drug’s safety, as it was associated with a
serious liver condition (veno-occlusive disease), which can be
fatal. Furthermore, the company failed to demonstrate that the
drug was of sufficient clinical benefit to patients enrolled in trials. Therefore, on June 21, 2010, the FDA informed healthcare
professionals and the public that the company was withdrawing
gemtuzumab from the market (FDA, 2010c).
4 Discussion
4.1 Outlook on the future use of the chimpanzee

What conclusions might this review suggest regarding the use
of the chimpanzee in biomedical research? For example, what
circumstances might have led to the apparent sharp reduction
in the use of chimpanzees? While some use likely continues
in private laboratories that do not publish their experiments,
a number of reasons point to a real and substantial reduction.
First, advances in biomedical technology and tools offer researchers alternative means of carrying out sophisticated investigations at a molecular level through in vitro and in silico
studies. Second, steep financial costs associated with the chimpanzee model are also a pragmatic and powerful factor. Of a
number of possible topics, we will look here briefly at the genetic and biological suitability of the chimpanzee, alternative
options for preclinical studies, and economic considerations in
drug development planning.
While ethical considerations are beyond the scope of this
article, they tangibly influence whether chimpanzees are used
and if so, the ways in which chimpanzee research currently is
conducted. Public opinion, which increasingly supports animal
welfare and non-animal research options, expresses societal
views in this respect (National Science Board, 2002; The Pew
Research Center for the People & the Press and The American
Association for the Advancement of Science, 2009). Both the
endangered status of the chimpanzee in the wild and ethical issues appear to influence the research policies of institutions in
many countries that restrict the use of the chimpanzee. Finally,
socially responsible companies find it possible to be responsive both to societal concerns and economic concerns of their
shareholders by using research methods that do not involve the
chimpanzee.
4.2 Suitability of the chimpanzee model

Historically, the chimpanzee model has relied on the phylogenetic closeness of chimpanzees to humans – first on the
morphological and phenotypic level and subsequently on the
research of blood components, including antigen epitopes
(Fridman, 2002). Indeed, in the 1980’s and 1990’s, much of
mAb research that used the chimpanzee was based on these as111
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sumptions and their study by immunological and cellular techniques. Today, however, molecular biology and the technology
it employs have moved on to other, more effective and successful research techniques and strategies, as has the scientific
understanding of many diseases.
The oft-repeated “1% difference” in our respective genomes
may make it appear that the difference between humans and
chimpanzees is negligible, but even these differences are actually significant both on the molecular and the gene expression level. For example, large-scale rearrangements, including deletion of entire genes, increase the DNA differential by
several percentage points (Perry et al., 2008). Of the specific
gene families, transcription factors that regulate gene expression and immune response genes have undergone significant
development since chimpanzee and human genomes diverged
(Chimpanzee Sequencing and Analysis Consortium, 2005).
In addition, the characterization of differences resulting from
our respective epigenetic and non-coding regulatory DNA has
barely begun (Weinstock, 2007).
Key differences in human and chimpanzee immune functions continue to be documented. Human lymphocytes appear to be over-reactive compared to those of the chimpanzee,
which is manifested in the outcome of some chronic diseases,
such as HIV and hepatitis. While it is not entirely clear what
the biological basis for this difference is, it has recently been
shown that this over-reactivity correlates with decreased levels
of inhibitory sialic acid-recognizing Ig-superfamily lectins on
human T and B cells (Soto et al., 2010). Among other carbohydrates, these molecules have important functions in protein
conformation and solubility and effector immune responses
(Nguyen, 2006). Also, NK cells that serve critical functions in
immunity are significantly different in humans and chimpanzees (Abi-Rached et al., 2010).
While the PK & PD data of small molecule drug clearance
and metabolism in the chimpanzee may in many respects be
comparable to that in humans, there are also many differences,
such as in the P450 enzyme activity and extrahepatic clearance, so that a simple assumption of overall comparability
would be difficult (Wong et al., 2004). Moreover, the PK & PD
of a mAb drug may vary by many additional factors, including
antigen expression and distribution and downstream immune
responses, as the mAb in question may have pleiotropic effects
(Gibson et al., 2009).
The history of approved mAb drugs that used the chimpanzee in their preclinical studies points to the difficulty of
predicting results in human patients based on this model. It
would not be appropriate to suggest that the preclinical chimpanzee studies should have disclosed all of the serious adverse
effects found later in humans. Because we deal here with
only three drugs, any statistical conclusions are not possible,
either. Nevertheless, it may not be prudent to dismiss without further investigation, as a mere coincidence, the fact that
two out of these three drugs were withdrawn from the market
because of their serious adverse effects on human patients,
particularly as this has not happened with the other approved
mAb drugs.

112

altex_2011_2_103_116_Bettauer.indd 112

4.3 Alternative models

Reactivity of the mAb to the target antigen is a key concern
when an animal model is selected for testing of a mAb drug.
In addition to the genetic sequence of the epitope itself, conformational and other structural issues affecting the mAb are
important. Preliminary in vitro testing usually is performed to
determine the likely in vivo function of the mAb in various species. For many mAbs, orthologous epitopes can be found among
a number of species, and only rarely would the chimpanzee appear to be the only species with cross-reactivity to the human
mAb drug candidate. Indeed, a mAb may be specific only to
humans. Such was the case with eculizumab, and in preclinical
studies a murine surrogate was used to test the drug’s toxicological effects (FDA, 2007).
To achieve the desired therapeutic effect, there may be two
or more alternative mechanisms that a mAb drug may employ.
For example, there are currently four approved mAb drugs to
treat TNFα-related conditions. The first drug, infliximab, was
approved in 1998 and used the chimpanzee in the preclinical
phase. Three other such drugs (adalimumab, certolizumab and
golimumab) subsequently have been approved without any indication in the FDA documents of the use of the chimpanzee.
Similarly, efalizumab was approved to treat psoriasis, using the
chimpanzee in its preclinical studies. In contrast, ustekimumab,
another psoriasis drug approved a few years later, did not rely
on the chimpanzee model (FDA, 2009a).
Even if the chimpanzee were the only non-human species that
recognizes a human mAb, satisfactory preclinical testing may
be possible through alternative means. Transgenic rodents may
in some cases express the relevant human antigen in a manner that allows PK & PD and toxicity studies. A surrogate mAb
also may cross-react and function in another animal species in a
manner similar to the mAb drug. Both of these approaches were
used in the preclinical studies for infliximab, which only crossreacted with the human and the chimpanzee. For infliximab, a
transgenic mouse was produced expressing human TNFα that
could then bind the mAb antagonist. Also, an anti-mouse TNFα
antibody surrogate was used in neutralization studies to study
the efficacy of the proposed mAb (FDA, 1998).
Increasingly sophisticated in vitro techniques are used to perform tests on relevant human cell lines. In many respects, these
tests are more useful than animal preclinical tests that may leave
open the questions of whether the markers used in them are the
most relevant ones for the purpose, and whether the results are
ultimately translatable to the human patient. Both pharmaceutical firms and regulatory authorities recognize the benefits of
research techniques that provide direct information about the
function of the drug candidate in the human patient.
Before recombinatorial genetic engineering and later mAb
technology advances, chimpanzee antibodies sometimes were
regarded as a surrogate in search for mAbs that could be used
in humans. For example, chimpanzees could be infected with a
pathogen in order to induce them to produce neutralizing antibodies that, in turn, could then be analyzed for optimal use in
a human vaccine (Crowe et al., 1994). Today, this use of the
chimpanzee is made redundant by a number of other, more ef-
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ficient means of developing mAbs with desired characteristics
(Almagro and Strohl, 2009).
In sum, a forward-looking mAb development plan may be
able to ensure that the use of the chimpanzee is unnecessary.
Current genetic information of candidate mAbs and their respective antigens in various species may permit the selection of
a mAb and an animal model, other than the chimpanzee, with
appropriate cross-reactivity and expression of antigens. In addition, in vitro testing may provide critical information about the
function of the drug candidate in human cells, or a surrogate alternative may be identified through a similar development plan
(Bhogal et al., 2008).
4.4 Economic considerations

Competition among pharmaceutical companies is intense in the
mAb field, and minimizing discovery and development costs is
an important consideration. Because use of the chimpanzee is
very expensive, the use of alternatives may provide pharmaceutical companies a competitive edge. As mentioned above, the
up-front selection of mAb candidates can take into account the
known biological characteristics of typical animal models in order to avoid obvious problems in cross-reactivity and expression
of antigens, among other things, in later preclinical studies.
Even if regulatory and ethical considerations were not an issue, the often uncertain benefit that might be derived from the
chimpanzee model can make it difficult to justify their use in
terms of the cost. The lack of hard data about chimpanzee biology in many respects (Wood, 2006), the less-than-systematical
pharmacological history, and the lack of statistical power in
chimpanzee studies leave a substantial margin of uncertainty
about the predictive quality of this model. Those mAb drugs
that have used the chimpanzee in their preclinical studies have
shown that the clinical success of such drugs is no better than
– and indeed, it appears not to be as good as – that of drugs
that did not use them.
Public funding of institutions and investigators that use the
chimpanzee in mAb research also raises significant issues of
public policy. A critical and unbiased review of the cost-effectiveness of such research would seem to be required at the time
when all areas of scientific research need to accomplish more
with fewer funds. Even if such scrutiny were not yet a formal requirement in institutional and funding reviews, both public accountability and fairness within the scientific community would
suggest that it be part of funding decisions.
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